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Inositol, Neural Tube Closure and the Prevention
of Neural Tube Defects
Nicholas D.E. Greene*, Kit-Yi Leung, and Andrew J. Copp
Susceptibility to neural tube defects (NTDs), such as anencephaly and spina
bifida is influenced by genetic and environmental factors including maternal
nutrition. Maternal periconceptional supplementation with folic acid
significantly reduces the risk of an NTD-affected pregnancy, but does not
prevent all NTDs, and “folic acid non-responsive” NTDs continue to occur.
Similarly, among mouse models of NTDs, some are responsive to folic acid
but others are not. Among nutritional factors, inositol deficiency causes
cranial NTDs in mice while supplemental inositol prevents spinal and cranial
NTDs in the curly tail (Grhl3 hypomorph) mouse, rodent models of
hyperglycemia or induced diabetes, and in a folate-deficiency induced NTD
model. NTDs also occur in mice lacking expression of certain inositol kinases.
Inositol-containing phospholipids (phosphoinositides) and soluble inositol
phosphates mediate a range of functions, including intracellular signaling,
interaction with cytoskeletal proteins, and regulation of membrane identity in
trafficking and cell division. Myo-inositol has been trialed in humans for a
range of conditions and appears safe for use in human pregnancy. In pilot
studies in Italy and the United Kingdom, women took inositol together with
folic acid preconceptionally, after one or more previous NTD-affected
pregnancies. In nonrandomized cohorts and a randomized double-blind study
in the United Kingdom, no recurrent NTDs were observed among 52
pregnancies reported to date. Larger-scale fully powered trials are needed to
determine whether supplementation with inositol and folic acid would more
effectively prevent NTDs than folic acid alone.
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Introduction
MATERNAL NUTRITION DURING PREGNANCY INFLUENCES
RISK OF NTDS
Failure in the process of neural tube closure during
embryonic development results in severe birth defects
termed neural tube defects, including anencephaly and
spina bifida. Patterns of inheritance of NTDs indicate a
major genetic contribution to risk of NTDs in the develop-
ing fetus, while it is also clear that non-genetic, environ-
mental, factors play a key role (Greene and Copp, 2014).
These may include exogenous agents including anti-
epileptic drugs, such as valproic acid, the mycotoxin fumo-
nisin or maternal exposures, such as high temperature
resulting from fever (Gelineau-van Waes et al., 2009; Wlo-
darczyk et al., 2012; Copp et al., 2013).
The area of most extensive study has been the poten-
tial contribution of maternal nutrition, given the observa-
tion that vitamin levels and risk of an affected pregnancy
were both associated with socioeconomic status (Leck,
1974; Smithells et al., 1976; Au et al., 2010). Attention has
particularly focused on vitamins relating to folate one-
carbon metabolism. Hence, maternal blood folate and vita-
min B12 status are independent risk factors for NTDs,
while elevated homocysteine, an inversely related bio-
marker of impaired folate status, is also associated with
NTDs (Kirke et al., 1993; Blom et al., 2006).
The corollary to NTD risk conferred by sub-optimal
maternal vitamin status is that supplementation with spe-
cific nutritional factors may have a protective effect. Clinical
trials have demonstrated a protective effect of periconcep-
tional folic acid supplementation against NTD recurrence
(after a first affected pregnancy) and occurrence (Smithells
et al., 1980; MRC Vitamin Study Research Group, 1991; Czei-
zel and Dudas, 1992). The clear evidence for a preventive
effect of folic acid led to recommendations that women
planning pregnancy should take a folic acid supplement.
In addition, public health initiatives to implement manda-
tory food fortification have been associated with a reduction
in NTD prevalence in many countries (Blencowe et al., 2010;
Crider et al., 2011; Rosenthal et al., 2014). Nevertheless, the
findings of clinical trials, monitoring of supplement use and
case studies of recurrent NTDs all indicate that some NTDs
are not preventable by folic acid (termed folic acid-resistant
or non-responsive) (MRC Vitamin Study Research Group,
1991; Mosley et al., 2009; Bupp et al., 2015).
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The recognition that some NTDs are not preventable by
folic acid engendered interest in other nutritional factors that
may contribute to prevention of NTDs. In this review, we
focus on a potential role for another nutrient, inositol.
INOSITOL AND ITS DERIVATIVES PARTICIPATE IN A DIVERSE
RANGE OF CELLULAR FUNCTIONS
Inositol (1,2,3,4,5,6-hexahydroxycyclohexane) is a naturally
occurring simple six carbon sugar alcohol, sometimes
referred to as a pseudo-vitamin (vitamin Bh or B8),
although it can be synthesized from glucose by means of
conversion of glucose 6-phosphate to inositol 1-phosphate
(Fig. 1). There are nine stereoisomers of inositol, of which
myo-, D-chiro-, scyllo-, epi-, muco-, and neo-inositol occur
naturally, with the predominant form being myo-inositol
(Michell, 2008; Leung et al., 2011). Adults typically con-
sume approximately 1 g of myo-inositol per day which is
present in a variety of foods including nuts, vegetables,
FIGURE 1. Outline of pathways for synthesis of inositol phosphates and phosphoinositides. Inositol can be obtained from dietary sources or synthesized from D-
glucose by the sequential action of hexokinase (HK), myo-inositol-1-phosphate synthase (MIPS), and inositol monophosphatase (IMPas). The structure of myo-
inositol and phosphatidylinositol are shown (inositol lipids are shaded gray). These molecules form the backbone for synthesis of inositol phosphate (IP) and
phosphoinositide (PI) molecules, mediated by action of multiple kinases and/or phosphatases. Enzymes that are discussed in the text are indicated (kinases in
blue text, phosphatases in purple text). Notably, several phosphorylation/dephosphorylation steps can be mediated by several enzymes. For example, a number
of kinases exist as multiple isoforms (e.g., PIP5K and PI3K [PI3-kinase]), while several phosphatases can act to dephosphorylate PI(3,4,5)P3 (e.g., INPP5E,
SHIP1, and SHIP2). In addition, some enzymes act at multiple steps (e.g. IPMK acts to phosphorylate inositol at a number of steps). Examples of downstream
functional effects of key molecules are indicated in italics (green text). PLC, phospholipase C; DAG, diacylglycerol; PKC, protein kinase C; IPMK, inositol phos-
phate multikinase; ITPK1, inositol 1,3,4-triphosphate 5/6 kinase.
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and citrus fruits (Holub, 1987; Croze and Soulage, 2013).
Plants, particularly legumes, oil seeds, and grains, are par-
ticularly rich in myo-inositol hexakisphosphate (IP6; phytic
acid); this is mostly hydrolyzed to free inositol before
absorption from the gut (Michell, 2008; Schlemmer et al.,
2009). However, owing to its ion-chelating properties, an
excess of phytate from dietary sources could theoretically
hinder absorption of cations, such as Ca21, from the gut
(Wilson et al., 2015). Myo-inositol in the nonphosphory-
lated form, typically available in vitamin supplements,
does not have this property. Although less abundant, D-
chiro-inositol is also obtained from dietary sources, princi-
pally in the methylated form 3-O-methyl-D-chiro-inositol
(pinitol) (Negishi et al., 2015).
Inositol is incorporated as the polar head-group of
membrane lipids based on phosphatidylinositol (PI),
which is synthesized from myo-inositol and cytidine
diphosphate-diacylglycerol (CDP-DAG). Hence, phosphoryl-
ation of inositol at carbons 3, 4, and 5 generates a series
of phosphoinositides which have multiple cellular func-
tions in signaling and membrane dynamics (Di Pietro and
De Camilli, 2006). When not bound to lipids, free inositol
can carry a phosphate group at each of its six carbons (IP1
to IP6). IP1, IP2, and IP3, are generated by hydrolysis of
PIP2 and subsequent recycling of inositol, while more
highly phosphorylated forms (IP4, IP5, and IP6) and pyro-
phosphates (e.g., PP-IP5 equivalent to IP7) are generated
by the action of specific kinases (Livermore et al., 2016).
Hence, intracellular inositol is present in a complex variety
of lipid-bound inositides as well as soluble inositol phos-
phates and pyrophosphates (Fig. 1).
Functions of phosphoinositides and inositol polyphosphates. The phos-
phoinositides PI(4,5)P2 and PI(3,4,5)P3 are key mediators
of major signaling pathways that influence diverse cellular
functions (Fig. 1). These pathways are reviewed exten-
sively elsewhere (Di Paolo and De Camilli, 2006; Michell,
2008; Bridges and Saltiel, 2015). In brief, hydrolysis of
PI(4,5)P2 by phospholipase C generates the second mes-
sengers inositol tri-phosphate (IP3) and diacylglycerol
(DAG). IP3 stimulates release of intracellular calcium while
DAG stimulates several isoforms of protein kinase C (Nish-
izuka, 1992; Berridge, 1993;). Alternatively, phosphoryla-
tion of PIP2 at the 3-position of inositol by PI3-kinases
generates PI(3,4,5)P3 which recruits downstream targets,
including the serine-threonine kinase Akt (Burgering and
Coffer, 1995; Larue and Bellacosa, 2005; Hawkins and Ste-
phens, 2015). The regulation of PI(3,4,5)P3 abundance by
activation of PI3-kinases and phosphatases such as PTEN
regulates a range of downstream cellular properties
including proliferation, motility and polarity (Tsujita and
Itoh, 2015).
In parallel with their role in signaling pathways, phos-
phoinositides interact with numerous proteins and thereby
provide an interface between membranes and the cytosol
in a wide range of cellular contexts (Janmey and Lindberg,
2004; Posor et al., 2015). Regulation of the abundance of
phosphorylated forms of PI involves the concerted action
of a series of different kinases and phosphatases. For
example, PI(4,5)P2 can be generated from PI(4)P by the
action of PI4P 5-kinases or to a much lesser extent from
PI(5)P by the action of PI5P 4-kinases (Fig. 1). There are
several family members for each kinase, together with sev-
eral corresponding phosphatases. Hence, there appears to
be a complex regulation of the abundance of differing PIs.
Localized activity of specific kinases and phosphatases is
thought to generate dynamic spatially restricted enrichment
of particular PIs which can modulate membrane dynamics
(Janmey and Lindberg, 2004; Saarikangas et al., 2010; Cauvin
and Echard, 2015). For example, coordination of endocytosis
and vesicle trafficking depends on specific PI pools. Clathrin-
mediated endocytosis requires PI(4,5)P2, with switching
between PI types providing compartment identity as vesicles
progress along the endocytic route (Croise et al., 2014; Posor
et al., 2015). PIs, particularly PI(4,5)P2, can be coupled to the
underlying F-actin cytoskeleton by means of “linker” proteins
such as class I myosins and Ezrin/Radixin/Moesin proteins,
while PIP2 can also suppress proteins such as cofilin that
mediate actin disassembly (Janmey and Lindberg, 2004; Tsu-
jita and Itoh, 2015). Modulation of PI metabolism, for exam-
ple through hydrolysis of PIP2, can thereby contribute to
local alterations in membrane-cytoskeleton tension during
cell shape changes and rearrangement (Tsujita and Itoh,
2015). These properties of various PIs are implicated in
membrane ruffling and micropinocytosis (Araki et al., 2007;
Posor et al., 2015) as well as several events during cell divi-
sion including spindle orientation, cell rounding and abcis-
sion (Field et al., 2005; Cauvin and Echard, 2015).
Among the proteins that interact with phosphoinositi-
des and/or link PIs to F-actin, a number are implicated in
neural tube closure and/or NTDs. For example, several of
the regulatory roles of PIs involve a close functional inter-
action with small GTPases, including Rac1, with which
they associate at the membrane. Notably, disruption of
cytoskeletal structure or turnover and impaired function
of small GTPases are implicated in NTDs in several mouse
models (Copp and Greene, 2010; Escuin et al., 2015; Rolo
et al., 2016). Loss of function of another protein, MARCKS,
which links PIP2 to the actin cytoskeleton also results in
NTDs in mice (Stumpo et al., 1995; McLaughlin et al.,
2002).
INOSITOL IS REQUIRED FOR NEURAL TUBE CLOSURE
Inositol deficiency causes cranial NTDs in mice. Interest in the influ-
ence of inositol levels on NTD predisposition was stimu-
lated by nutritional studies in which rat embryos were
cultured in defined conditions through the period of neu-
ral tube closure (Cockroft, 1979, 1988). Specific omission
of several vitamins caused growth retardation or develop-
mental abnormalities but NTDs occurred only in the
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absence of inositol. Similarly, deficiency of inositol in the
culture medium causes cranial NTDs in mouse embryos,
whereas deficiency of other vitamins, including folic acid,
does not (Cockroft et al., 1992). Although inositol defi-
ciency caused cranial NTDs among non-mutant strains of
mice, increased sensitivity was observed among cultured
embryos of the curly tail (ct) strain, which are genetically
predisposed to spinal and cranial NTDs (Cockroft et al.,
1992). Under normal conditions curly tail embryos show
only around 3 to 7% incidence of cranial NTDs (exence-
phaly). However, inositol-deficiency caused much higher
rates of cranial NTDs (70%) and an increased concentra-
tion of inositol was required to correct these defects than
in other strains tested (Cockroft et al., 1992).
Inositol metabolism and neural tube defects in mouse models. Analysis
of mice carrying gene-trap alleles that result in loss or
diminished expression of inositol kinases suggests that
both phosphoinositides and inositol polyphosphates play
key cellular functions essential for neural tube closure.
Cranial NTDs occur in embryos lacking PIP5KIc, one of
three isoforms of phosphatidylinositol-4-phosphate 5-
kinase that mediates synthesis of PI(4,5)P2 (Wang et al.,
2007). Of interest, cranial NTDs also occur in mice lack-
ing inositol polyphosphate 5-phosphatase E (encoded by
Inpp5E), which hydrolyses PI(4,5)P2 or PI(3,4,5)P3, and
hence opposes the effect of PIP5KIc on levels of PI(4)P
(Jacoby et al., 2009). Given the functions of PI(4,5)P2 not
only as substrate for phospholipase C-mediated signaling
by means of diacylglycerol and IP3 but also in membrane
identity/trafficking, cytoskeletal organization and cell divi-
sion, impaired production could potentially disturb neuru-
lation through several different cellular mechanisms.
Recent studies suggest an additional possible mecha-
nism relating to a requirement for regulation of phosphoi-
nositides in regulating biogenesis and stability of primary
cilia. PIP5KIc localises to the basal body of cilia and
appears to be essential for ciliogenesis, probably by
depleting PI(4)P (Chavez et al., 2015; Xu et al., 2016). In
contrast, Inpp5E opposes the action of PIP(5)KIc during
initial events of ciliogenesis (Xu et al., 2016), but appears
to be required within established cilia to maintain their
structural stability (Bielas et al., 2009; Plotnikova et al.,
2015). Hence, phosphoinositide homeostasis appears to
play a key role in cilia formation and function. In addition
to cranial NTDs, mice lacking Inpp5E exhibit features of
ciliopathies such as polycystic kidneys and polydactyly
(Jacoby et al., 2009), while mutations in INPP5E are found
in the ciliopathies Joubert Syndrome and MORM Syndrome
(Bielas et al., 2009; Jacoby et al., 2009). Notably, cranial
NTDs are observed in several other mouse mutants in
association with abnormal cilia (Murdoch and Copp,
2010).
In addition to phosphoinositides, several functions
have been ascribed to inositol phosphates beyond the
function of IP3 in intracellular calcium signaling. In partic-
ular, generation of higher inositol polyphosphates appears
to be required during the stage of neural tube closure.
Mice that are deficient for Ipmk, encoding an inositol phos-
phate multikinase (Impk, also known as Ipk2), fail to
develop beyond E9.5 (Frederick et al., 2005). Furthermore,
embryos with reduced expression of Itpk1, encoding inosi-
tol 1,3,4,-triphosphate 5/6-kinase show growth retardation
and cranial NTDs (frequency of 12%) (Wilson et al.,
2009). These inositol kinases are crucial for production of
the highly phosphorylated forms of inositol IP4, IP5, and
IP6, the most abundant of which within cells is inositol
hexakisphosphate (IP6) (Wilson et al., 2015). Impk may
also act as a PI3-kinase and can mediate transcriptional
regulation through kinase-independent functions (Kim
et al., 2015).
Intriguingly, IP4 has been found to play a key role in
modulating Rho GTPase activity and F-actin during epithe-
lial repair in Xenopus embryos (Soto et al., 2013). Given
the requirement for Rho kinase-dependent regulation of
actomyosin turnover during mammalian neurulation
(Escuin et al., 2015), it is tempting to speculate that inosi-
tol polyphosphates could directly influence the closure
process.
Glycosylphosphatidylinositol-anchored proteins and NTDs. In addition to
PIs and IPs, inositol forms a structural component of gly-
cophosphoinositide (GPI) anchors that link many different
proteins to cell surfaces (Englund, 1993; Paulick and Ber-
tozzi, 2008). Inositol glycans, derived from hydrolysis of
GPI-anchors, are also proposed to act as second messen-
gers in certain signaling reactions responsive to insulin
(Nascimento et al., 2006; Croze and Soulage, 2013).
Although GPI-anchors may represent only a small pro-
portion of cellular inositol it is intriguing that cranial
NTDs arise in knockout mice for genes encoding several
different GPI-anchored proteins including Rgma (repulsive
guidance molecule A; Niederkofler et al., 2004), Efna5
(ephrinA5) (Holmberg et al., 2000), and Folr1
(folate receptor 1, folate-binding protein1; Piedrahita
et al., 1999). Moreover, treatment of cultured embryos
with phosphatidylinositol-specific phospholipase C, which
cleaves GPI anchors, disturbs spinal neural tube closure
(O’Shea and Kaufman, 1980; Abdul-Aziz et al., 2009).
INOSITOL SUPPLEMENTATION IN MODELS OF NTDS
Uptake of inositol by the embryo and generation of inosi-
tol phosphoinositides and inositol polyphosphates are
required for cranial neurulation (Table 1). This raises the
question of whether supplemental inositol may prevent
NTDs in some models.
Prevention of spina bifida in the curly tail mouse. Although inositol
deficiency was found to exacerbate cranial NTDs (see
above), the main neural tube closure phenotype in the
curly tail strain involves a defect of spinal neurulation
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affecting approximately 50% of embryos. Failure to com-
plete closure of the posterior neuropore (PNP) at the end
of spinal neurulation results in spina bifida in around 15%
of embryos. A further 35 to 40% exhibit only a tail flexion
defect, a phenotype which results from delayed completion
of PNP closure (Van Straaten and Copp, 2001). Unlike in
the cranial region, inositol deficiency did not further exac-
erbate the progression of spinal neurulation in cultured
curly tail embryos or delay closure in the nonmutant CBA/
Ca strain (Greene and Copp, 1997). However, increasing
the myo-inositol concentration normalized PNP closure in
cultured embryos (Greene and Copp, 1997). This protec-
tive effect was confirmed by in vivo supplementation by
means of maternal intra-peritoneal injection, oral dosing
or subcutaneous infusion (Greene and Copp, 1997; Cogram
et al., 2002), with each strategy leading to a significant
reduction in the frequency of spina bifida.
Interestingly, an alternative enantiomer of inositol, D-
chiro-inositol showed a greater protective effect than myo-
inositol, with a larger reduction in incidence of spina
bifida at the same dose, and maintained effectiveness even
at a lower dose (Cogram et al., 2002). Whether myo- and
chiro-inositol act through the same mechanism is still
unknown. Interconversion of the two enantiomers can be
mediated by an endogenous epimerase (Pak et al., 1992;
Sun et al., 2002), although other groups report limited
interconversion in vivo (Lin et al., 2009). Notably, NTDs in
the curly tail model are not preventable by folic acid and
provide a model for “folic acid-resistant” NTDs. Identifica-
tion of a protective therapy such as inositol, therefore,
raises the question of whether this approach may also
have utility in preventing some human NTDs.
Supplemental inositol could potentially act to overcome
the underlying causative defect responsible for NTDs and/
or enhance the normal processes required for progression
of neural tube closure. Completion of PNP closure does
not occur prematurely in nonmutant embryos supple-
mented with inositol (Greene and Copp, 1997), which
would argue that inositol may prevent NTDs by normaliz-
ing an underlying developmental abnormality. In the curly
tail model, spina bifida results from a proliferation defect
in the hindgut endoderm (Copp et al., 1988). This creates
a growth imbalance between dorsal and ventral tissues,
leading to increased ventral curvature of the caudal region
of the embryo that mechanically opposes closure leading
to spina bifida (Brook et al., 1991). This defect is thought
TABLE 1. Experimental Models in Which Inositol Status or Metabolism Is Associated with Neural Tube Closure
Inositol-related deficits in NTD causation NTD type Comments/mechanism Reference
Inositol deficiency Cultured mouse or rat embryos Exencephaly NTDs in non-mutant and
mutant strains. Higher
incidence in ct strain
Cockroft, 1992
PI4P5KIc null PIP kinase generates PI(4,5)P2 Exencephaly Disordered actin
Cilia defect?
Wang, 2007
Inpp5e null PI(4,5)P2 and PI(3,4,5)P2
phosphatase
Exencephaly Unstable cilia and ciliopathy
phenotypes
Jacoby, 2009




Deficit of higher IPs Wilson, 2009
NTD prevention by inositol in experimental models
Curly tail mouse Embryo culture; Oral; I.P.
injection; sub-cutaneous
route
Spina bifida Corrects proliferation defect.
Requires activity of PKC
isoforms. Chiro-inositol more
effective than myo-inositol
Greene, 1997; Cogram, 2002;
Cogram, 2004




Diabetes Streptozotocin-induced diabetes Exencephaly Restores inositol levels? Khandelwal, 1998
Folate-deficient NTDs Dietary folate deficiency in
wild-type strain (ct genetic
background)
Exencephaly Unknown Burren, 2010
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to result from reduced expression of the transcription fac-
tor Grhl3. The curly tail strain is homozygous for a hypo-
morphic allele of Grhl3 and reinstatement of Grhl3
expression normalizes spinal neurulation (Ting et al.,
2003; Gustavsson et al., 2007).
However, penetrance of defects is also strongly influ-
enced by modifiers in the genetic background, such as a
polymorphic variant of lamin B1 (de Castro et al., 2012).
Inositol supplementation increases proliferation in the
hindgut endoderm of curly tail embryos, which would
explain the preventive effect on spinal NTDs (Cogram
et al., 2004). Consistent with this hypothesis, spina bifida
was also found to be preventable by combinations of thy-
midine and purine nucleotides, which also normalize pro-
liferation in the hindgut (Leung et al., 2013).
In cultured embryos labelled inositol is taken up and
incorporated into inositol phosphates and inositol-
containing phospholipids. This appears to be necessary for
inositol’s protective effect in curly tail embryos as inhibi-
tion of inositol phosphate recycling abolishes the protec-
tive effect (Greene and Copp, 1997). Increased production
of PtdIns(4,5)P2 could potentially have a direct ameliorat-
ing effect on the underlying proliferation defect in curly
tail embryos, owing to the its functions in cell division
(Cauvin and Echard, 2015). In addition, among potential
downstream effects following PtdIns(4,5)P2 hydrolysis,
activation of protein kinase C appears to play a key role in
prevention of spinal NTDs because the protective effect of
inositol is (i) mimicked by short-term treatment with a
phorbol ester activator of PKC, and (ii) abrogated by broad
spectrum and isoform-specific PKC inhibitors (Greene and
Copp, 1997; Cogram et al., 2004).
Inositol does not prevent NTDs in all models. The protective effect of
inositol against spina bifida is not universal in mouse NTD
models. For example, while prevention of NTDs in the
curly tail model was confirmed in an independent labora-
tory, no response was observed among Grhl3 null mice
(Ting et al., 2003). This is likely due to the greater severity
of NTDs, which are fully penetrant in the complete knock-
out of Grhl3 compared with diminished expression in the
curly tail hypomorph. In the context of cranial NTDs, it is
also possible that inositol acts in the curly tail strain to
normalize effects of genetic modifiers rather than the
effects of Grhl3 mutation. For example, cranial NTDs in
the curly tail strain appear to largely be a feature of the
genetic background as, unlike spina bifida, they are not
prevented by transgenic reinstatement of Grhl3 expression
(Sudiwala et al., 2016). Spinal closure defects in the Bent
tail mouse, carrying an X chromosome deletion that
encompasses Zic3 (Franke et al., 2003; Klootwijk et al.,
2004), and in Mekk4 knockouts (Chi et al., 2005) were
also found to be unresponsive to inositol treatment.
Inositol and susceptibility to NTDs conferred by maternal diabetes. NTDs
occur in cultured rat and mouse embryos exposed to hyper-
glycemia or streptozotocin-induced diabetes (Sadler, 1980;
Cockroft, 1984), both of which elicit depletion of tissue ino-
sitol levels (Hod et al., 1986; Sussman and Matschinsky,
1988; Hashimoto et al., 1990). Supplementation with inosi-
tol in cultured embryos corrects the hyperglycemia-induced
growth retardation and NTDs (Baker et al., 1990; Hashimoto
et al., 1990; Hod et al., 1990). Similarly, oral administration
of myo-inositol led to a reduction in the frequency of
diabetes-induced abnormalities in rat embryos (Khandelwal
et al., 1998) (Table 1).
Supplemental inositol restores tissue inositol levels, but
could plausibly also act through pathways downstream of ino-
sitol phosphates or phosphoinositides. Arachidonic acid can be
derived from diacylglycerol which is produced upon hydrolysis
of PIP2. The protective effect of inositol against hyperglycemia
in vitro is reversed by indomethacin, an inhibitor of arachi-
donic acid metabolism (Baker et al., 1990). Conversely, arachi-
donic acid and some derivative prostaglandins have a
protective effect against NTDs in the hyperglycinemia and
streptozotocin models (Goldman et al., 1985; Pinter et al.,
1986). Whether inositol acts to prevent hyperglycemia and/or
diabetes-related NTDs through stimulating arachidonic acid
signaling, upstream of prostaglandins and leukotrienes, or this
pathway is required in parallel with inositol for cranial neuru-
lation is not clear. Unlike, phorbol esters, arachidonic acid did
not substitute for inositol in prevention of spinal NTDs in the
curly tailmodel (Greene and Copp, 1997).
Prevention of NTDs resulting from folate deficiency?. While inositol
reduces NTD frequency in the curly tail mouse, in which
folic acid is not preventive, it is important to ask whether
inositol can also prevent NTDs in models that are respon-
sive to folic acid. Supplemental folic acid has been found
to reduce the frequency of NTDs resulting from mutation
of the Pax3 transcription factor in the Sp2H and Sp (alleles
of Splotch mice) models (Fleming and Copp, 1998;
Wlodarczyk et al., 2006), whereas myo-inositol was not
protective (Wlodarczyk et al., 2006). In dietary models,
folate-deficiency does not cause NTDs unless in the pres-
ence of a predisposing genetic mutation or background,
such as Pax3 deficiency (Burren et al., 2008; Heid et al.,
1992). Embryos with a genetic background similar to the
curly tail strain but wild-type for Grhl3 (1ct/1ct) do not
develop cranial NTDs under normal dietary conditions but
exhibit exencephaly when made folate-deficient (Burren
et al., 2010). As expected, NTDs in this model can be pre-
vented by maternal administration of folic acid. Notably,
however, myo-inositol has a similar protective effect (Bur-
ren et al., 2010), raising the possibility that in some cir-
cumstances inositol could overcome NTD-predisposing
abnormalities imposed by sub-optimal folate status. In this
context, we cannot currently rule out a role for inositol, by
means of its GPI-anchor function, in promoting enhanced
folate uptake by means of Folr1.
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INOSITOL STATUS AND HUMAN NTDS
Few studies have systematically determined maternal inosi-
tol status in relation to NTD risk. Estimates of dietary myo-
inositol intake from a food frequency questionnaire did not
suggest a strong association with risk of NTDs (Shaw et al.,
2005). Moreover, determination of serum myo-inositol con-
centration in mothers and their infants with spina bifida did
not show significant variation from controls (63–102 sub-
jects in each group), although a trend toward lower values
was recognized (Groenen et al., 2003). However, among the
lowest maternal serum myo-inositol concentrations (lowest
decile), there was a significant association with having a
child with spina bifida (Groenen et al., 2003). If these find-
ings are representative of maternal inositol status during
pregnancy, one could speculate that insufficient inositol may
contribute to development of NTDs in the offspring. Further
studies on this relationship are warranted as evidence sug-
gests that blood myo-inositol levels may change during
pregnancy (Groenen et al., 2006). Of note, in a more recent
study in which samples were collected during pregnancy,
maternal plasma IP6 was found be significantly diminished
among NTD cases compared with controls (60 in each
group) (Guan et al., 2014).
Considering potential genetic influences on inositol
uptake or metabolism, analysis of variants in a myo-inosi-
tol transporter, SLC5A11, did not suggest an association
with spina bifida in a Dutch population (Groenen et al.,
2004). However, investigation of maternal ITPK1 genotype,
whose deficiency can cause NTDs in mice (Wilson et al.,
2009), suggests a potential role in NTDs. A single nucleo-
tide polymorphism (SNP) -based case–control analysis in a
Chinese population, revealed a significant association of
NTD with four tag SNPs in maternal ITPK1 that was prin-
cipally attributable to association with spina bifida. Among
the associated SNPs, rs3783903 also appeared to be pre-
dictive of lower ITPK1 expression in blood and plasma
inositol levels (Guan et al., 2014).
INOSITOL SUPPLEMENTATION IN HUMAN PREGNANCY
The findings of a preventive effect of a nutrient supple-
ment, such as inositol, in rodent NTD models raises sev-
eral questions, including: (1) are inositol supplements safe
to use during pregnancy in humans, and (2) could inositol
prevent some human NTDs?
In mouse studies, neither myo- nor chiro-inositol had
notable side-effects in the supplemented dams or in the
developing fetuses (Cogram et al., 2002). As described
above, inositol supplementation has beneficial effects in
several NTD models without apparent deleterious effects.
However, in mice treated with valproic acid, an anti-
epileptic with known teratogenic properties, inositol was
found to exacerbate the induced developmental abnormal-
ities (Massa et al., 2006). Use of anti-epileptics was an
exclusion criterion in a subsequent clinical trial of inositol
during pregnancy (Greene et al., 2016).
In adult humans, inositol has been tested for a variety
of conditions (Table 2), including psoriasis, panic disorder,
depression, and eating disorders (Benjamin et al., 1995;
Levine et al., 1995; Chengappa et al., 2000; Gelber et al.,
2001; Allan et al., 2004). Daily dosage ranging from 6 g to
as high as 18 g did not result in major side effects,
although mild flatulence or diarrhea was reported by a
few patients. No side effects have been reported for doses
less than 6 g per day. Overall, the outcomes of studies in
adults do not suggest that supplemental inositol has dele-
terious effects (Croze and Soulage, 2013).
An important additional consideration in any potential
novel periconceptional preventive therapy for NTDs is the
requirement for safety in the fetus and pregnant mother.
The inositol concentration is higher in reproductive organs
than in blood, and concentration in the ovaries is under
hormonal control (Lewin et al., 1982). Several clinical tri-
als in women with polycystic ovary syndrome have sug-
gested a beneficial effect of inositol (myo- or chiro-)
supplements in improving ovarian function, hormone sta-
tus and menstrual activity, with no reported side effects at
typical doses of 2 to 4 g daily (Table 2; Nestler et al.,
1999; Gerli et al., 2007; Genazzani et al., 2008; Costantino
et al., 2009; reviewed by Dinicola et al., 2014).
Furthermore, similar doses of inositol have been tri-
aled in randomized studies during pregnancy for treat-
ment and/or prevention of gestational diabetes (Corrado
et al., 2011; D’Anna et al., 2013; Matarrelli et al., 2013), as
well as in postmenopausal women with metabolic syn-
drome (Giordano et al., 2011). These studies were based
on the hypothesis that inositol would be beneficial, as
myo- and D-chiro-inositol and their methylated derivatives
(sequoyital and D-pinitol, respectively) were reported to
have insulin-sensitizing properties in experimental models
of hyperglycemia and diabetes (Croze and Soulage, 2013).
In women considered at risk owing to a family history of
type 2 diabetes (D’Anna et al., 2013) or elevated fasting
glucose (Matarrelli et al., 2013), there was a lower inci-
dence of gestational diabetes in the myo-inositol group
compared with placebo. Supplementation (2 g inositol,
twice daily) throughout pregnancy from the first trimester
onward was not associated with side effects or increased
risk of adverse pregnancy outcomes (reviewed by Croze
and Soulage, 2013; Noventa et al., 2016).
PREVENTION OF NTDS BY INOSITOL?
Taking into account the prevalence of NTDs, the sample
size required for investigation of a potential novel therapy
in a “first occurrence” trial is likely to be prohibitively
large. As a result, inositol supplementation has so far been
studied solely in women with one or more previous NTD-
affected pregnancies (Table 2). Such women are known to
be at considerably higher risk of a subsequent NTD-
affected pregnancy than women without a history of
NTDs: the recurrence risk after a single affected pregnancy
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is typically quoted as 3.1%, rising to 11.8% after two
affected pregnancies (Seller, 1981). A cohort of 12 women
in Italy took myo-inositol and folic acid pre- and postcon-
ceptionally after at least one previous affected pregnancy.
Folic acid use was reported in the majority of their previ-
ous pregnancies which suggests that most of these NTDs
were “folic acid-resistant”. Fifteen subsequent pregnancies
were followed up and 17 babies were born without NTDs
(Cavalli and Copp, 2002; Cavalli et al., 2011). These find-
ings encourage the view that there may be a contribution
of inositol toward prevention of NTD recurrence. However,
the number of pregnancies was too small to draw firm
conclusions and the nonrandomized study design was a
potential source of bias.
Where ethically and logistically possible, a randomized
controlled trial is generally considered the optimal
approach to determine the efficacy of a novel therapy.
Given the known protective effect of folic acid, it would be
unethical to conduct a trial without providing it to all par-
ticipants. Hence, a potential trial design would test
whether inositol 1 folic acid is more effective than pla-
cebo 1 folic acid. The MRC Vitamin Study recruited
around 1800 women who had a previous NTD-affected
pregnancy and the outcome of 1200 subsequent pregnan-
cies was ascertained (approximately 600 in the combined
folic acid supplemented groups and 600 in combined non-
folic acid groups). The recurrence rate in the folic acid
groups was 1% compared with 3.5% in the other groups.
TABLE 2. Clinical Use of myo-Inositol
Condition
Study size (total inositol
and placebo groups)
Dose (daily, myo-inositol
unless stated) Outcome References
Adult conditions
Psoriasis in patients taking lithium 15 6 g for 1 week Beneficial effect in psoriasis Allan, 2004
Bulimia nervosa and binge eating 12 18 g for 6 weeks Indication of therapeutic value Gelber, 2001
Add-on treatment for bipolar disorder 24 12 g 6 weeks Indication of beneficial effect Chengappa, 2000
Panic disorder 21 12 g for 4 weeks Decline in frequency & severity Benjamin, 1995
Depression 28 12 g for 4 weeks Improved score in depression
scale
Levine, 1995
Metabolic syndrome 80 2 g for 6 months Improved blood pressure
parameters
Giordano, 2011
Treatment prior to or during pregnancy
Polycystic ovary syndrome 20 2 g for 12 weeks Improved insulin sensitivity &
menstrual cycle activity
Genazzani, 2008
Polycystic ovary syndrome 92 4 g for 14 weeks Impoved ovarian function Gerli, 2007
Polycystic ovary syndrome 42 4 g for 12–16 weeks Improved insulin sensitivity &
ovulation
Costantino, 2009
Elevated fasting glucose 75 4 g throughout pregnancy Reduced incidence of
gestational diabetes
Matarrelli, 2013
Risk of gestational diabetes 220 2 g from 1st trimester Reduced incidence of
gestational diabetes
D’Anna, 2013
Gestational diabetes 69 4 g for 8 weeks Decline in fasting glucose Corrado, 2011
NTDs - recurrence 12 non-randomised
(15 pregnancies)
0.5 or 1 g daily to
60 days pregnancy
No recurrent NTDs (0/17
babies)
Cavalli and Copp, 2002
Cavalli, 2011
NTDs - recurrence 47 randomised
22 non-randomised
1 g daily to 12 weeks
pregnancy (1 folic acid)
No NTDs among pregnancies
in inositol groups (14 rando-
mised and 21 non-rando-
mised). 3 NTDs in non-
supplemented groups
Greene, 2016
Examples of conditions in which myo-inositol has been tested for potential beneficial effects.
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Detection of a further significant reduction in recurrence
rate, due to inositol supplementation, should require a
similar or larger sample size.
Another consideration is that any trial for prevention
of NTDs now takes place in the context of use of folic acid
supplement use and/or food fortification on a population
level, including among women without a previous history
of NTDs. Hence, it could be hypothesized that those NTDs
which occur now may be more enriched for folic acid–
non-responsive NTDs than at the time of the folic acid tri-
als in the 1980s, when use of folic acid supplements was
not widespread. Similar lack of response in a subsequent
pregnancy would thus lead to a higher rate of recurrence
than in the MRC Vitamin Study. However, in the United
Kingdom, it is estimated that only around 30 to 35% of
women take periconceptional folic acid (Bestwick et al.,
2014) and food fortification is not in place. Therefore, the
likely recurrence rate in a folic acid supplemented study
group is difficult to predict.
A pilot double-blind randomized clinical trial of inositol
was performed in the United Kingdom, with recruitment
during 2009 to 2013 to make further progress toward
determining whether use of inositol supplements with
folic acid would have a greater protective effect than folic
acid alone. The PONTI (Prevention Of Neural Tube defects
by Inositol) study recruited women with one or more pre-
vious affected NTD pregnancies, who were planning a fur-
ther pregnancy (Greene et al., 2016). The study design
involved randomization of equal numbers of pregnancies
to inositol (1 g daily) 1 folic acid (5 mg daily) or placebo
1 folic acid groups and, among 99 eligible women who
contacted the study center, 47 agreed to be randomized.
The majority of randomized women (46 of 47) had a his-
tory of one previous affected pregnancy (31 spina bifida
and 15 anencephaly; one woman had two previous preg-
nancies with anencephaly). Among 14 established preg-
nancies in the inositol 1 folic acid group, all led to the
birth of unaffected babies. Among 19 established pregnan-
cies in the placebo 1 folic acid group, 18 led to normal
outcomes, while one fetus was diagnosed with anence-
phaly on ultrasound (Greene et al., 2016).
One aim of the study was to evaluate the feasibility of
recruiting women at “high risk” of an NTD pregnancy into
a randomized study. In fact, many women (around half of
those who contacted the study team) were unwilling to
enter the randomized study; almost all cited the possibility
of inclusion in the placebo group as their reason for
declining randomization. This was despite provision of
folic acid to all participants and the unproven nature of
inositol’s preventive effect. A cohort of 22 women who
met the eligibility criteria for the PONTI study but decided
against randomization, agreed to be followed up in subse-
quent pregnancies. Among this nonrandomized group 19
women, 6 of whom had experienced two previous affected
pregnancies, used peri-conceptional supplementation with
folic acid (at least 5 mg daily) and inositol (typically 1 g
daily). They reported 21 pregnancies without NTDs. A fur-
ther three nonrandomized women, who subsequently took
only 5 mg folic acid reported one normal pregnancy out-
come and two pregnancies that were terminated following
a diagnosis of anencephaly.
CONCLUSIONS AND FUTURE PROSPECTS
Inositol, inositol phosphoinsitides, and inositol polyphos-
phates are a group of molecules that fulfil a diverse range
of cellular functions. Supply and metabolism of inositol is
required for cranial neural tube closure, while supplemen-
tal inositol can prevent spinal and cranial NTDs in various
experimental models. Notably, these include the curly tail
strain, whose multigenic causation perhaps models the eti-
ology of human NTDs more representatively than single
gene knockouts. In addition, inositol has been implicated
in ameliorating NTDs in diabetes-induced and folate-
deficiency models, each of which are implicated in human
NTDs. Exogenous inositol could potentially act to over-
come the underlying causative defect responsible for NTDs
and/or enhance the normal processes required for pro-
gression of neural tube closure. Indeed, in the curly tail
model, inositol has been found to counteract the geneti-
cally determined imbalance of cell proliferation in the
region of caudal neurulation. Given the multiple functions
of inositol in differing cellular signaling pathways and
processes it is also plausible that there are differing meta-
bolic and cellular mechanisms underlying the effects of
inositol in the cranial and spinal regions and in the vari-
ous models where it has been shown to act. Further stud-
ies will address these questions.
Clinical use of inositol in adults and during pregnancy
does not indicate safety concerns at the doses tested to date
and beneficial effects on development of gestational diabetes
have been reported. In the context of NTD prevention, the
findings of recent non-randomized and randomized studies
are encouraging but these studies are currently of insufficient
size to demonstrate a significant protective effect of inositol.
Moreover, studies to date have been recurrence trials so the
effect of inositol on first occurrence of NTDs has not yet been
formally investigated. We propose that a fully powered
randomized controlled study is justified to test whether ino-
sitol 1 folic acid has a greater protective effect against NTDs
than folic acid alone. Such a study will likely require a multi-
site, multi-country design. Nevertheless, if inositol does prove
to be protective it is a simple, inexpensive compound that
could potentially be used on a population-wide level, to fur-
ther enhance primary prevention of NTDs.
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